MedPage Today5h
Obesity Contributes to Top Killer; 22% Weight Loss With Novel Agent; PCOS Challenges
Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
Medical News Today11h
Calorie restriction plus common diabetes drug leads to higher remission rates
A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...
Healio1h
FDA approves new indication for Ozempic to lower kidney risks in type 2 diabetes, CKD
The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and ...
US FDA approves Novo Nordisk's diabetes drug to reduce risk of worsening kidney disease
Novo Nordisk said on Tuesday the U.S. FDA has approved its diabetes drug Ozempic to reduce the risk of worsening kidney ...